The second plenary meeting of the PREDICTION-ADR consortium was held in Uppsala, September 15 and 16, 2015.
On the first day of meeting, the recruitment of patients to both the statin-induced myopathy and the angiotensin-converting inhibitor-induced angioedema arms studies, was discussed. Recruitment of both discovery cohorts has been completed and the focus is now on final recruitment of patients for the replication cohorts.
On day 2 the focus was on sequencing harmonization studies carried out in preparation for sequencing DNA samples in the main studies. Studies at the Universities of Dundee, Liverpool and Uppsala showed very consistent data between all three centers. This means that everything is now ready for sequencing the samples in the principal PREDICTION-ADR studies, which is due to begin.
Prediction-ADR aims to discover the genetic factors predisposing patients to adverse drug reactions from cardiovascular disease drugs. The project has received funding from the European Union’s Seventh Framework Program for research, technological development and demonstration under grant agreement no 602108.
For further information see Prediction-ADR-Newsletter